<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917357</url>
  </required_header>
  <id_info>
    <org_study_id>QVX-V-D001</org_study_id>
    <nct_id>NCT01917357</nct_id>
  </id_info>
  <brief_title>A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject</brief_title>
  <official_title>A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem® DTwP-HepB-Hib) in Uniject™ With Quinvaxem® Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to show that vaccination with three doses of Quinvaxem presented in Uniject&#xD;
      is not inferior to vaccination with three doses of Quinvaxem presented in single dose vials,&#xD;
      with respect to protection against all antibodies (anti-hepatitis B surface antibodies,&#xD;
      anti-polyribosyl ribitol phosphate (PRP), anti-diphtheria, anti-tetanus and anti-Bordetella&#xD;
      pertussis) one (1) month after completion of the 6-10-14 week vaccination course.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-PRP Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-hepatitis B Surface Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-diphtheria Toxoid Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-tetanus Toxoid Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate: Anti-B. Pertussis Antibodies</measure>
    <time_frame>1 month after the third vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Tetanus</condition>
  <condition>Hepatitis B</condition>
  <condition>Haemophilus Infections</condition>
  <arm_group>
    <arm_group_label>Quinvaxem in Uniject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose (0.5 mL) of Quinvaxem contains:&#xD;
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen&#xD;
One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using the Uniject pre-filled injection device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinvaxem in single dose vials</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single dose (0.5 mL) of Quinvaxem contains:&#xD;
diphtheria antitoxin (&gt;= 30 IU), tetanus antitoxin (&gt;= 60 IU), whole-cell inactive pertussis bacteria (&gt;= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen&#xD;
One dose of Quinvaxem given intramuscularly at Weeks 6, 10 and 14 by injection into the anterolateral region of the thigh using a needle and syringe from single dose vials</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem in Uniject</intervention_name>
    <arm_group_label>Quinvaxem in Uniject</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quinvaxem in single dose vials</intervention_name>
    <arm_group_label>Quinvaxem in single dose vials</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A male or female between, and including, 42 and 64 days of age at the time of the&#xD;
             first vaccination&#xD;
&#xD;
          -  Written informed consent obtained from parents/legal guardians of the subject&#xD;
&#xD;
          -  Free of obvious health problems as established by medical history and/or clinical&#xD;
             examination before entering the study&#xD;
&#xD;
          -  HepB vaccination at birth (within 48 hours)&#xD;
&#xD;
          -  Available for all scheduled study visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any investigational drug or any investigational vaccine in the 30 days&#xD;
             preceding the first dose of study vaccine, or their planned use during the study&#xD;
             period and safety follow-up&#xD;
&#xD;
          -  Planned administration of a vaccine not foreseen by the Study Protocol&#xD;
&#xD;
          -  Known or suspected impairment of immune function, known HIV-positivity; actively&#xD;
             receiving immunosuppressive therapy, or in receipt of systemic immunosuppressive&#xD;
             therapy in the one month prior to study entry (note: inhaled and topical steroids are&#xD;
             allowed)&#xD;
&#xD;
          -  Administration of parenteral immunoglobulin preparation and/or blood products since&#xD;
             birth&#xD;
&#xD;
          -  Previous vaccination against Hib and/or DTP&#xD;
&#xD;
          -  History of anaphylaxis, or any serious vaccine reaction, or hypersensitivity to any&#xD;
             vaccine component or to products containing mercury compounds, such as thiomersal&#xD;
&#xD;
          -  Clinically significant acute infection&#xD;
&#xD;
          -  Clinically significant acute illness&#xD;
&#xD;
          -  Any condition that, in the opinion of the investigator, might interfere with the&#xD;
             evaluation of the study objectives&#xD;
&#xD;
          -  Participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>64 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria RZ Capeding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine (RITM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine</name>
      <address>
        <city>Muntinlupa City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>July 12, 2014</last_update_submitted>
  <last_update_submitted_qc>July 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <keyword>Virus</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Haemophilus Influenzae</keyword>
  <keyword>Immunity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Haemophilus Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

